We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Antibiotic resistance: a global health problem
- Intersection between machines and biology
- AI in biology
- Can computers create an antibiotic?
- Molecular sequence space is astronomical: opportunity for AI
- Antibiotic design by computers - evolution
- Antibiotic design by computers
- Antibiotic design by computers - Guavanin 2
- AI innovation
- Antibiotics discovered using AI kill bacteria in animals
- Can computers accelerate antibiotic discovery? (1)
- Developing drugs is slow and expensive
- Can computers accelerate antibiotic discovery? (2)
- Computer-guided antibiotic discovery
- Mining proteins for antibiotic discovery
- The human proteome: a source of antibiotics
- Encrypted peptides display anti-infective activity in abscess infection model
- Encrypted peptides can be expressed physiologically
- Our closest relatives: neanderthals and denisovans
- Molecular de-extinction: life, resurrected
- Molecular de-extinction: new antibiotic discovery framework
- Mechanism of action of ancient and modern encrypted peptides
- Anti-infective activity of ancient and modern encrypted peptides
- APEX: a new AI model
- Mining ancient biology for new antibiotics
- Mining ancient biology for new antibiotics
- Anti-infective activity of antibiotics from extinct organisms
- Why molecular de-extinction?
- Molecular de-extinction (1)
- Molecular de-extinction (2)
- Antibiotics AI: next steps
- Mining the tree of life for antibiotics
- The global microbiome
- Lachnospirin-1 and Enterococcin-1
- The human gut microbiome
- Prevotellin-2
- Discovering antibiotics at digital speed
- Antibiotics AI
- A new world of preclinical antibiotics discovered by AI
- Acknowledgments
- Financial disclosure
Topics Covered
- Antibiotic resistance
- Intersection between machines and biology
- AI in biology
- Antibiotic design by computers
- Drug development
- Human proteome
- Molecular de-extinction
- AI for antibiotic discovery
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
de la Fuente, C. (2025, October 30). AI for antibiotic discovery [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 30, 2025, from https://doi.org/10.69645/UHJF4267.Export Citation (RIS)
Publication History
- Published on October 30, 2025
Financial Disclosures
- Cesar de la Fuente is a co-founder of, and scientific advisor, to Peptaris, Inc., provides consulting services to Invaio Sciences, and is a member of the Scientific Advisory Boards of Nowture S.L., Peptidus, European Biotech Venture Builder, the Peptide Drug Hunting Consortium (PDHC), ePhective Therapeutics, Inc., and Phare Bio.
A selection of talks on Microbiology
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my name is
Cesar de la Fuente,
and I'm a Presidential
Associate Professor at
University of Pennsylvania.
Today I'd like to tell you about
how we've been using,
for a number of years now,
artificial intelligence
approaches for
antibiotic discovery.
0:18
Antibiotic resistance is a
huge global health problem.
It affects every
corner of the world.
I could make the case that it is
the most underinvested area that
affects the most
people in the world.
We can see here,
currently antimicrobial-resistant
infections—these are
bacterial infections,
they are associated with
millions of deaths
every single year.
The current projection
is that by 2050,
that number is going
to go up to about
10 million deaths per
year around the world.
As we can see here
that this is going to
surpass every other
major cause of death in
our society, including
cancer, diabetes,
and many other causes of death.
If we do a quick calculation,
those 10 million deaths
per year actually
correspond to about one
death every three seconds.
Really, this is a huge
global health problem that
affects really all of us,
and we can refer to it as
a silent pandemic where
we need to do
something about it.
Throughout my whole career,
I've been really passionate
about this huge problem,
and I have been trying to
think of out-of-the-box
methods or
approaches to try
to counter AMR.
1:31
In my lab, I'm really
fortunate to be
working at this
intersection between
machines and biology.
We believe that
by using the power of machines,
we can accelerate discoveries in
biology and medicine,
including antibiotic discovery.
I'm really fortunate
to be able to
work with people that
come to my lab from
all walks of life and from
many different
parts of the world.
Many of them have
different ways of
thinking about problems and
they have different expertise.
To give you an example,
right now in my lab
we have people with
computer science backgrounds,
with chemistry backgrounds,
people that are microbiologists,
engineers, and so on.
We all work together to try to
tackle a lot of the things that
I'm going to describe today.
I'm going to talk about
all of this chronologically and
how I got into this
field and so on.